3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
7
Neoplasms
3
Skin Neoplasms
1
Sarcoma
1
Refractory Differentiated Thyroid Gland Carcinoma
1
Neoplasm Metastasis
1
Fever
1
Differentiated Thyroid Cancer (DTC)
1
Ameloblastoma
1
Interventions
liposomal amphotericin B
2
Vancomycin
2
Cefepime
2
trametinib
1
pegfilgrastim
1
dabrafenib
1
ceftobiprole medocaril
1
Tazobactam
1
Piperacillin, Tazobactam Drug Combination
1
Piperacillin
1
Levofloxacin
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Filgrastim
1
Ciprofloxacin
1
Caspofungin
1
Bevacizumab
1
Anti-Bacterial Agents
1
Amoxicillin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Fever
×
dabrafenib
×
Clear all
NCT03551626
2025-04-29
COMBI-APlus
Novartis
Phase 3
Completed
552 enrolled
12 charts